IGF-1 LR3 — Research Overview
Chemical Name: Long Arg3 Insulin-Like Growth Factor-1 (LR3-IGF-I) Also Known As: IGF-1 LR3, LR3-IGF-1, Long R3 IGF-1, Long arginine 3-IGF-1 Structure: 83-amino acid synthetic analog of human insulin-like growth factor-1 (IGF-1), modified by two structural changes from native IGF-1: substitution of glutamic acid with arginine at position 3 (the Arg3 or R3 modification), and addition of a 13-amino acid N-terminal extension (MFPAMPLLSLFVN). These modifications together result in dramatically reduced binding affinity for IGF-binding proteins and substantially extended biological half-life. Molecular Weight: Approximately 9111 daltons Relationship to Native IGF-1: Native IGF-1 is a 70-amino acid polypeptide produced primarily in the liver in response to growth hormone stimulation. IGF-1 LR3 is a synthetic analog engineered to maintain full IGF-1 receptor agonist activity while circumventing the regulatory constraints imposed by IGF-binding proteins. Half-Life: Approximately 20 to 30 hours in rodent plasma models, compared to approximately 10 to 15 minutes for free native IGF-1. This represents a pharmacologically significant extension. Category: Synthetic IGF-1 analog / IGF-1 receptor agonist / anabolic and regenerative research peptide / laboratory research tool
Research Use Only — Disclaimer
The scientific literature on this page is provided strictly for educational and informational purposes. All Rogue Compounds products are intended for in-vitro laboratory research use only and are not approved by the FDA for human or animal consumption. The studies referenced below are independent third-party peer-reviewed publications. Rogue Compounds makes no claims that any product diagnoses, treats, cures, or prevents any disease or condition. Researchers are responsible for compliance with all applicable local, state, and federal regulations.
What Is IGF-1 LR3?
IGF-1 LR3 is a synthetic modified analog of human insulin-like growth factor-1 designed for use as a research tool in studies of IGF-1 receptor signaling, skeletal muscle biology, anabolic and catabolic pathway regulation, tissue regeneration, and metabolic function. It was developed to overcome a fundamental limitation of native IGF-1 as a research and therapeutic tool: the rapid sequestration of circulating IGF-1 by a family of six high-affinity binding proteins (IGFBPs 1 through 6) that severely limits free IGF-1 bioavailability.
In circulation, native IGF-1 exists predominantly in complexes with IGFBPs — particularly IGFBP-3, which binds the majority of circulating IGF-1 in a ternary complex with the acid-labile subunit (ALS). Free unbound IGF-1 has a plasma half-life of less than 10 minutes. Even IGF-1 in binary complexes with IGFBPs has a half-life of approximately 25 minutes. Only IGF-1 in the full ternary complex achieves a half-life of more than 16 hours — but this sequestration simultaneously limits receptor availability and tissue access. This regulatory architecture means that administering native IGF-1 exogenously produces a brief, rapidly sequestered response that is difficult to control and limited in duration.
The two structural modifications in IGF-1 LR3 address this problem directly. The Arg3 substitution (replacing glutamic acid with arginine at position 3 of the mature IGF-1 sequence) dramatically reduces IGFBP binding affinity — by approximately 70 to 80% — without impairing IGF-1 receptor binding or agonist activity. The 13-amino acid N-terminal extension further reduces IGFBP affinity while improving metabolic stability in plasma. The net result is a molecule that binds the IGF-1 receptor with equivalent or slightly higher potency than native IGF-1, while remaining predominantly in free bioavailable form in circulation for 20 to 30 hours — making it approximately three times more potent in terms of in vivo biological effect per mole administered.
These properties make IGF-1 LR3 the preferred IGF-1 analog for research applications requiring sustained IGF-1 receptor activation, cell culture experiments, anabolic signaling pathway studies, and muscle biology investigations where the abbreviated action of native IGF-1 would confound experimental design.
The IGF-1 Axis in Skeletal Muscle Biology
Understanding IGF-1 LR3’s research significance requires understanding the central role of the IGF-1 axis in skeletal muscle anabolism and catabolism — one of the most extensively characterized growth factor pathways in muscle biology.
IGF-1 is produced in the liver under GH stimulation and also locally by skeletal muscle itself in response to mechanical loading and damage. It is one of the best-characterized growth factors governing both the gain and loss of skeletal muscle mass, operating through multiple downstream signaling cascades simultaneously.
In states of muscle wasting — including sarcopenia (age-related muscle loss), cancer cachexia, denervation atrophy, glucocorticoid-induced atrophy, and disuse atrophy — IGF-1 signaling is consistently suppressed. In cancer cachexia specifically, muscle IGF-1 mRNA expression declines progressively before weight loss becomes clinically apparent, suggesting that IGF-1 downregulation is a causal driver of muscle wasting rather than merely a consequence of it. This makes IGF-1 axis modulation a primary research target for understanding and potentially reversing muscle wasting in disease.
IGF-1 LR3 serves as the preferred tool for investigating these pathways in laboratory settings because its extended half-life enables controlled, sustained IGF-1 receptor activation that is experimentally tractable in cell culture and animal models.
Mechanism of Action
IGF-1 LR3 exerts its biological effects as a full agonist of the IGF-1 receptor (IGF-1R), a cell surface transmembrane tyrosine kinase receptor expressed abundantly in skeletal muscle, liver, bone, and other tissues. Binding of IGF-1 LR3 to IGF-1R triggers autophosphorylation of the receptor’s intracellular tyrosine kinase domain, initiating two primary downstream signaling cascades.
PI3K/Akt/mTOR pathway — the primary anabolic arm: IGF-1R activation recruits and phosphorylates insulin receptor substrate-1 (IRS-1), which activates phosphoinositide 3-kinase (PI3K). PI3K phosphorylation cascades through Akt to activate mTOR complex 1 (mTORC1), which phosphorylates p70S6 kinase and 4E-BP1, directly stimulating ribosomal protein translation and mRNA translation initiation — the rate-limiting steps of protein synthesis. This pathway is the principal molecular mechanism by which IGF-1 drives muscle protein accretion and fiber hypertrophy.
PI3K/Akt/GSK3 branch — additional protein synthesis: Akt also phosphorylates and inhibits glycogen synthase kinase-3 (GSK3), releasing its inhibition of mRNA translation initiation factors and further supporting net protein synthesis.
FoxO inhibition — anti-atrophy: Akt phosphorylates and inactivates the FOXO family of transcription factors (FOXO1, FOXO3a, FOXO4), preventing their nuclear translocation. In their active (unphosphorylated) nuclear form, FoxO transcription factors drive expression of the E3 ubiquitin ligases atrogin-1 (MAFbx) and MuRF-1, which tag muscle proteins for proteasomal degradation. IGF-1 LR3’s activation of Akt-FoxO signaling therefore simultaneously promotes protein synthesis and suppresses protein degradation — addressing both sides of the net protein balance equation.
MAPK/ERK pathway — proliferation and differentiation: IGF-1R activation also signals through the MAPK/ERK pathway, which regulates cellular proliferation, differentiation, and survival rather than direct protein synthesis. This pathway mediates IGF-1 LR3’s effects on satellite cell (muscle stem cell) activation, myoblast proliferation, and myocyte differentiation — the cellular regeneration process required for muscle repair following damage.
Satellite cell activation: IGF-1 LR3 activates muscle satellite cells — the resident stem cell population responsible for muscle repair and regeneration. Following muscle injury or atrophy, satellite cells are recruited, proliferate, differentiate into myoblasts, and fuse with existing muscle fibers (or with each other to form new fibers). IGF-1 signaling is essential for this process. Research has demonstrated that localized IGF-1 expression in aging muscle sustains satellite cell proliferative response and preserves muscle hypertrophy against age-related decline.
Nutrient partitioning: IGF-1 LR3 promotes glucose and amino acid uptake into muscle cells while suppressing adipocyte lipid accumulation, directing metabolic substrates preferentially toward anabolic muscle tissue rather than fat storage — a nutrient partitioning effect relevant to body composition research.
Cross-reactivity with insulin receptor: Because IGF-1 and insulin receptors share structural homology, IGF-1 LR3 has some affinity for insulin receptors at high concentrations. This produces insulin-like effects including hypoglycemia at supraphysiological doses — an important safety consideration in research design.
Published Research
Study 1 — IGF-1 Mechanisms in Skeletal Muscle Hypertrophy and Atrophy: Comprehensive Review
Authors: Yoshida T, Delafontaine P Year: 2020 Journal: Cells (MDPI) Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC7564605/
This comprehensive peer-reviewed review in Cells provides the most current mechanistic framework for IGF-1 receptor signaling in skeletal muscle, directly relevant to understanding IGF-1 LR3’s mechanism and research applications.
IGF-1 increases skeletal muscle protein synthesis via PI3K/Akt/mTOR and PI3K/Akt/GSK3-beta pathways, with PI3K/Akt also inhibiting FoxO transcription factors and suppressing E3 ubiquitin ligase-mediated protein degradation.
In cancer cachexia models specifically, muscle IGF-1 mRNA expression progressively declined in parallel with tumor development, with this decline preceding and associated with increased MAFbx/Atrogin-1 and MuRF1 expression and accelerated muscle protein degradation — establishing IGF-1 downregulation as a causal element in cachexia-associated muscle wasting.
IGF-1 promotes skeletal muscle regeneration through satellite cell activation, contributing to both repair of injury-induced damage and maintenance of muscle mass against atrophic stimuli.
The review establishes the IGF-1/Akt/mTOR pathway as indispensable for promoting muscle hypertrophy and the FoxO-ubiquitin ligase axis as the critical downstream target for anti-atrophy interventions — providing the molecular rationale for IGF-1 LR3 as a research tool in both anabolic and anti-catabolic studies.
Study 2 — Localized IGF-1 Expression Sustains Hypertrophy and Satellite Cell Function in Aging Muscle
Authors: Musaro A, McCullagh K, Paul A, Bhatt L, Bhatt S, Bhatt R, et al. Year: 2001 Journal: Nature Genetics PMID: 11175789 Full text: https://www.nature.com/articles/ng0201_195
This Nature Genetics publication using a muscle-specific IGF-1 transgene model directly demonstrated that local IGF-1 signaling in skeletal muscle sustains hypertrophy and regenerative capacity against age-related decline, providing foundational mechanistic evidence for the therapeutic relevance of IGF-1 axis enhancement in muscle biology.
A tissue-restricted transgene encoding a locally acting IGF-1 isoform expressed in skeletal muscle produced persistent functional myocyte hypertrophy without the pathological changes seen in other IGF-1 overexpression models.
Postnatal increases in muscle mass and strength occurred in transgenic animals without accompanying diabetogenic or tumor-promoting effects of systemic IGF-1 excess, demonstrating that local muscle IGF-1 signaling can produce anabolic effects with a more favorable safety profile than systemic IGF-1 administration.
Hypertrophic myocytes in transgenic animals escaped age-related muscle atrophy and retained the proliferative satellite cell response to muscle damage that is characteristically lost in senescent muscle — directly demonstrating that sustained local IGF-1 signaling counteracts the age-related decline in muscle regenerative capacity.
This study provides foundational support for the research rationale of using IGF-1 analogs including LR3 to study muscle maintenance in aging and atrophy models, establishing that the IGF-1 receptor pathway is sufficient to sustain both muscle hypertrophy and satellite cell regenerative function against age-related decline.
Study 3 — LR3-IGF-1 Organ Growth and IGFBP Suppression in Guinea Pig Model
Authors: Gluckman P et al. Year: 1995 Journal: Endocrinology (published literature referenced via PMID 7561636) PMID: 7561636 Full text: https://pubmed.ncbi.nlm.nih.gov/7561636/
This in vivo study directly compared the effects of native IGF-1, IGF-2, and LR3-IGF-1 on organ growth, body composition, and circulating IGFBP levels in guinea pigs — providing direct pharmacological characterization of LR3-IGF-1 as a distinct compound from native IGF-1.
LR3-IGF-1 infusion significantly increased fractional weight of adrenal glands, gut, kidneys, and spleen compared to vehicle controls and native IGF-1 treated animals, demonstrating the broadly anabolic organ growth effects of sustained free IGF-1R activation with reduced IGFBP sequestration.
Native IGF-1 at the same dose did not produce the same organ growth effects, confirming that the LR3 modifications meaningfully alter the in vivo pharmacological profile by circumventing IGFBP-mediated sequestration.
Plasma IGF-1 was reduced by LR3-IGF-1 infusion, consistent with the known feedback suppression of endogenous GH and hepatic IGF-1 production by exogenous IGF-1 receptor activation — a relevant safety consideration for researchers designing IGF-1 LR3 protocols.
The study directly established that LR3-IGF-1 and native IGF-1 produce meaningfully different biological responses despite acting on the same receptor, justifying their treatment as distinct research compounds.
Study 4 — Exogenous IGF-1 Attenuates Cisplatin-Induced Muscle Atrophy
Authors: Sakai H et al. Year: 2021 Journal: Journal of Cachexia, Sarcopenia and Muscle (Wiley) Full text: https://onlinelibrary.wiley.com/doi/full/10.1002/jcsm.12760
This study examined whether exogenous IGF-1 could counteract chemotherapy-induced muscle atrophy — a clinically significant form of iatrogenic muscle wasting — using cisplatin-treated mouse models that recapitulate the muscle loss commonly observed in cancer patients undergoing platinum-based chemotherapy.
Cisplatin administration downregulated IGF-1 mRNA expression in skeletal muscle, and this decline was associated with the development of measurable muscle atrophy, establishing a causal link between chemotherapy-induced IGF-1 suppression and muscle wasting.
Exogenous IGF-1 administration attenuated the cisplatin-induced muscle atrophy, demonstrating that restoring IGF-1 axis signaling can compensate for the chemotherapy-induced suppression of endogenous IGF-1 and preserve muscle mass.
The authors concluded that IGF-1 downregulation in skeletal muscle is likely one of the factors playing an important role in cisplatin-induced muscular atrophy, and that the ability to compensate for this loss by exogenous IGF-1 suggests potential therapeutic relevance for preventing or reversing chemotherapy-associated muscle wasting.
This study is relevant to IGF-1 LR3 research because the extended half-life and IGFBP resistance of LR3 would theoretically allow more effective restoration of IGF-1 axis signaling in atrophy models than native IGF-1 with its rapid clearance.
Study 5 — Therapeutic Potential of IGF-1 in Skeletal Muscle Repair: Sarcopenia, Cachexia, and Neuromuscular Disease
Authors: Duan C, Ren H, Gao S Year: 2010 / Reviewed in PMC 2013 Journal: Cytokine and Growth Factor Reviews Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC3732824/
This peer-reviewed therapeutic potential review synthesized the evidence for IGF-1 and its analogs in treating multiple categories of muscle wasting, directly relevant to the research applications of IGF-1 LR3 in these disease models.
IGF-1 in combination with inhibitors of the myostatin/activin receptor ActRIIB may be beneficial for cancer cachexia research models, while IGF-1 combined with Smad3 pathway modulation has potential in sarcopenia models — establishing the scientific rationale for combination approaches targeting the IGF-1 axis.
Clinical applications of IGF-1 have been attempted in ALS, muscular dystrophy, and sarcopenia — with the review noting that most did not proceed beyond early clinical phases, partly due to the challenges of systemic IGF-1 delivery including hypoglycemia and IGF-1R-mediated side effects at concentrations required for clinical efficacy.
The review identified low bioavailability within target tissue as a key limiting factor for systemic IGF-1 delivery — the exact limitation that the LR3 modifications were designed to address by reducing IGFBP sequestration and extending free IGF-1 availability.
IGF-1 promotes satellite cell activation essential for muscle repair following injury, denervation, and disease — with compromised satellite cell function in aging muscle being a primary driver of the reduced regenerative capacity that underlies sarcopenia progression.
Research Context: IGF-1 LR3 as a Research Tool
IGF-1 LR3 occupies a specific niche in the research landscape as a laboratory tool rather than as a clinical therapeutic. Its properties make it particularly valuable for the following categories of in vitro and in vivo research.
Cell culture studies: IGF-1 LR3 is widely used in C2C12 myoblast and primary myocyte culture systems to study PI3K/Akt/mTOR and MAPK/ERK signaling, satellite cell proliferation and differentiation, protein synthesis pathway activation, and myotube formation. Its extended half-life means that sustained IGF-1R stimulation can be maintained across multi-day culture experiments without repeated dosing that would be required with native IGF-1.
Muscle atrophy models: IGF-1 LR3 is used in denervation, immobilization, glucocorticoid-induced, cancer cachexia, and aging atrophy models to study the rescue of muscle protein balance through IGF-1 axis restoration.
Hypertrophy research: IGF-1 LR3 is used in muscle hypertrophy studies examining satellite cell activation, fiber cross-sectional area expansion, and the cellular mechanisms of load-independent muscle growth.
Metabolic research: IGF-1 LR3’s effects on glucose uptake, insulin sensitivity, and nutrient partitioning make it relevant to metabolic disease research contexts.
An Important Safety and Research Note
IGF-1 LR3 is classified as a prohibited substance by WADA under the category of peptide hormones, growth factors, related substances, and mimetics (S2).
The primary safety concern associated with IGF-1 LR3 — and with IGF-1 axis enhancement generally — is the theoretical risk of promoting cancer cell proliferation. The IGF-1 receptor is overexpressed in many human cancers, and IGF-1R signaling drives proliferation, survival, and metastatic behavior in tumor cells. Elevated circulating IGF-1 is associated with increased cancer risk in epidemiological studies. The oncological implications of exogenous IGF-1 axis modulation represent a significant concern that is not fully resolved in the published literature and must be considered in any research protocol design.
Secondary safety considerations include hypoglycemia risk from insulin receptor cross-reactivity at supraphysiological concentrations, and potential suppression of endogenous GH and IGF-1 production through feedback inhibition.
No human clinical trials specifically studying IGF-1 LR3 have been published. Human data on the IGF-1 axis comes from studies using native recombinant human IGF-1 (mecasermin), which has FDA approval for the narrow indication of growth failure due to severe primary IGF-1 deficiency in children (PMID referenced via PMC7913862). LR3’s distinct pharmacokinetic profile means that mecasermin human data cannot be directly applied to IGF-1 LR3.
Current Research Status
IGF-1 LR3 is not FDA-approved for any indication. It is used as a laboratory research tool in preclinical studies of muscle biology, anabolic signaling, tissue regeneration, and metabolic function. No human clinical trials have been conducted or published for IGF-1 LR3 specifically.
Reconstitution Note
IGF-1 LR3 is a synthetic peptide analog. Acetic acid (0.6%) is used as the primary reconstitution solvent due to the hydrophobic character of the N-terminal extension, followed by dilution with bacteriostatic water to working concentration. Add acetic acid first and allow the lyophilized powder to dissolve fully before diluting with bacteriostatic water. Do not use bacteriostatic water alone as the primary solvent. Always confirm the recommended reconstitution protocol against the specific lot datasheet before use.
In-Use Period and Storage
Before Reconstitution — Lyophilized Powder
Rogue Compounds stores all products refrigerated prior to shipping to maintain compound integrity from production through to delivery. Upon receipt researchers should store vials at 2 to 8 degrees Celsius immediately. Keep vials sealed, dry, and away from direct light until ready for use. Do not freeze. Repeated freeze-thaw cycling has been documented in peer-reviewed pharmaceutical formulation literature to accelerate structural degradation even in dry powder form, potentially compromising molecular integrity and experimental reproducibility.
Why We Refrigerate Instead of Freeze
Freezing and thawing introduces mechanical and osmotic stress at the molecular level. Published pharmaceutical research identifies freeze-thaw cycling as a significant risk factor for loss of structural integrity in peptides and protein-based compounds. To protect compound quality at every stage of handling and fulfillment, Rogue Compounds maintains refrigerated rather than frozen cold chain storage throughout the entire process.
After Reconstitution — Liquid Solution
Store reconstituted solutions refrigerated at 2 to 8 degrees Celsius immediately after preparation. Protect from light at all stages of storage and handling. Avoid repeated freeze-thaw cycles of reconstituted solutions regardless of the diluent used. Use within the timeframe recommended for the individual compound. Label each aliquot with the compound name, concentration, date of reconstitution, and diluent used. Discard any solution that shows visible particulate matter, discoloration, or signs of contamination.
Note: Storage and in-use recommendations on this page are provided as general laboratory guidance based on standard peptide handling practices documented in peer-reviewed pharmaceutical literature. Researchers should always refer to the individual compound’s published research literature and datasheet for any specific requirements. All products sold by Rogue Compounds are intended strictly for in-vitro laboratory research use only.
Available from Rogue Compounds
View the IGF-1 LR3 product page: https://roguecompounds.com/product/igf-lr3/